Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $7.4 million.

  • Kymera Therapeutics' Depreciation & Amortization (CF) rose 8.15% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 31.72%. This contributed to the annual value of $7.4 million for FY2024, which is 106.82% up from last year.
  • As of FY2024, Kymera Therapeutics' Depreciation & Amortization (CF) stood at $7.4 million, which was up 106.82% from $3.6 million recorded in FY2023.
  • Kymera Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $7.4 million for FY2024, and its period low was $1.8 million during FY2020.
  • In the last 3 years, Kymera Therapeutics' Depreciation & Amortization (CF) had a median value of $3.6 million in 2023 and averaged $4.6 million.
  • Data for Kymera Therapeutics' Depreciation & Amortization (CF) shows a peak YoY spiked of 113.70% (in 2020) over the last 5 years.
  • Over the past 5 years, Kymera Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $1.8 million in 2020, then soared by 35.96% to $2.4 million in 2021, then increased by 24.20% to $3.0 million in 2022, then grew by 19.75% to $3.6 million in 2023, then spiked by 106.82% to $7.4 million in 2024.